This trial represents a decade of work—hypothesis → design → accrual → follow-up → data lock → Presented at @ASTRO_org 2025 plenary →publication in @JCO_ASCO
https://t.co/nPBHKp9VPN
🙏 To the patients, families, clinicians, and my team: A BIG thank you.
Protocol Activation! NRG-CC017: A randomized phase III study comparing temporally-modulated pulsed radiation therapy (TMPRT) versus standard radiation therapy with temozolomide for adults with newly diagnosed MGMT-unmethylated glioblastoma https://t.co/OufdYFBx0F
Anthropic fucking killed it (again). biggest ai product launch of the year so far.
claude can now control your entire computer autonomously. anything you can do on a computer - claude can. your very own digital employee.
- any app, browser, file, spreadsheet, tool claude can intelligently access and operate.
- claude controls your entire screen (like a human), no connectors. this is a huge step-up in intelligence.
- best part: you can text claude to do things from your phone and it'll do work on your computer!
- in the last week anthropic has shipped 9 features that have built up to this: a fully automated digital human.
unreal
Heading to RSNA 2025?
Come visit AAPM at booth #1108 and learn all about medical physics and more!
Find out more information here: https://t.co/u6kAJN0M9x
A touching tribute.
https://t.co/fHBs54mm03
It is impossible to overstate what Ed meant to our Montefiore Einstein community.
It is also impossible to overstate how much work we still need to do as cancer researchers...
@MontefioreNYC@EinsteinMed
Very happy to present a mathematical framework for inverse design of brachy applicators today at #ABS . Seems like a crowd favorite from the comments. Future of Brachy is bright!
Manuscript coming in hot.
I am proud to share the announcement about our CodeMender project at @GoogleDeepMind, an agent that can automatically fix a range of code security vulnerabilities. From only a modest-compute run, our agent submitted 72 high-quality fixes to vulnerable code in popular codebases, and maintainers accepted and upstreamed them.
https://t.co/TApULhUSzB
After a very successful council row yesterday w VC the best Ana Maria, we are back at it again. I’ll be at the table later today 4-5PM. Please come talk to me #AAPM2025
The first generative AI drug to get to a Phase 2 randomized clinical trial. The small molecule in pill form, rentosertib, showed signs of efficacy for idiopathic pulmonary fibrosis @NatureMedicine@InSilicoMeds
https://t.co/zPd7ud00oQ
@DrSpratticus Dr. Spratt, since the model is referencing some literature by quick search, indexing NCCN guidelines can generate clinically grounded responses. Not sure of the legality of it though.
This will grab headlines but they used the ChatGPT 4 model which is for basic reasoning, which I would not consider tumor board to fit this. The o3 model actually reasons and would be at least a fighting chance.
I have put it to the test with very complex scenarios with sufficient input and appropriate prompts and does exceptional.
@OpenAI